2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Sunday, November 10, 2019

9:00AM-11:00AM: Antiphospholipid Syndrome Poster

9:00AM-11:00AM: Cytokines & Cell Trafficking Poster

9:00AM-11:00AM: Education Poster

9:00AM-11:00AM: Education/Community Programs Poster – ARP

9:00AM-11:00AM: Epidemiology & Public Health Poster I: RA

9:00AM-11:00AM: Epidemiology & Public Health Poster I: RA – ARP

9:00AM-11:00AM: Fibromyalgia & Other Clinical Pain Syndromes Poster

9:00AM-11:00AM: Health Services Research Poster I – ACR/ARP

9:00AM-11:00AM: Imaging Of Rheumatic Diseases Poster I

9:00AM-11:00AM: Innate Immunity Poster

9:00AM-11:00AM: Measures Of Healthcare Quality Poster I: Testing, Screening, & Treating

9:00AM-11:00AM: Metabolic & Crystal Arthropathies Poster I: Clinical

9:00AM-11:00AM: Miscellaneous Rheumatic & Inflammatory Disease Poster I: Fibroinflammatory & Granulomatous Disorders & Therapies

9:00AM-11:00AM: Muscle Biology, Myositis & Myopathies Poster I

9:00AM-11:00AM: Patient Outcomes, Preferences, & Attitudes Poster I: Patient Reported Outcomes

9:00AM-11:00AM: Pediatric Rheumatology – ePoster I: Basic Science, Biomarkers, & Sclerodermic Fever

9:00AM-11:00AM: Pediatric Rheumatology – ePoster I: Basic Science, Biomarkers, & Sclerodermic Fever – ARP

9:00AM-11:00AM: RA – Diagnosis, Manifestations, & Outcomes Poster I: Risk Factors, Predictors, & Prognosis

9:00AM-11:00AM: RA – Etiology & Pathogenesis Poster I

9:00AM-11:00AM: RA – Treatments Poster I: Novel Treatments

9:00AM-11:00AM: SLE – Animal Models Poster

9:00AM-11:00AM: SLE – Clinical Poster I: Epidemiology & Pathogenesis

9:00AM-11:00AM: SLE – Clinical Poster I: Epidemiology & Pathogenesis – ARP

9:00AM-11:00AM: Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Axial Spondyloarthritis, Clinical Features

9:00AM-11:00AM: Systemic Sclerosis & Related Disorders – Clinical Poster I

9:00AM-11:00AM: T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

9:00AM-11:00AM: Vasculitis – Non-ANCA-Associated & Related Disorders Poster I: Takayasu's Arteritis & Polymyalgia Rheumatica

11:00AM-12:30PM: 3S032: Plenary I (805–809)

11:30AM-1:30PM: Patient Perspectives Poster Session

2:30PM-4:00PM: 3S074: Epidemiology & Public Health I: Risk Factors & Outcomes for Rheumatic Diseases (821–826)

2:30PM-4:00PM: 3S075: Fibromyalgia & Other Clinical Pain Syndromes (827–832)

2:30PM-4:00PM: 3S076: Patient Outcomes, Preferences, & Attitudes I: Patient Reported Outcomes (833–838)

2:30PM-4:00PM: 3S077: Pediatric Rheumatology – Basic Science (810–814)

2:30PM-4:00PM: 3S078: RA – Diagnosis, Manifestations, & Outcomes I: Pulmonary & Other Comorbidities (839–844)

2:30PM-4:00PM: 3S079: RA – Etiology & Pathogenesis I (815–820)

2:30PM-4:00PM: 3S080: RA – Treatments I: Safety and Outcomes (845–850)

2:30PM-4:00PM: 3S081: SLE – Clinical I: Clinical Trials (857–862)

2:30PM-4:00PM: 3S083: Spondyloarthritis Including Psoriatic Arthritis – Clinical I: Imaging in Axial Spondyloarthritis & Psoriatic Arthritis (851–856)

2:30PM-4:00PM: 3S084: Systemic Sclerosis & Related Disorder – Clinical I: Therapeutics & Outcomes (863–868)

2:30PM-4:00PM: 3S085: Vasculitis – ANCA-Associated I (869–874)

2:30PM-4:00PM: 3S092: New Approaches to Old Diseases (875–879)

4:30PM-6:00PM: 3S089: Health Services Research I: Clinical Perspectives (951–956)

4:30PM-6:00PM: 3S100: B Cell Biology & Targets in Autoimmune & Inflammatory Disease (880–885)

4:30PM-6:00PM: 3S101: Epidemiology & Public Health II: SLE (892–897)

4:30PM-6:00PM: 3S102: Metabolic & Crystal Arthropathies I: Clinical (898–902)

4:30PM-6:00PM: 3S104: Miscellaneous Rheumatic & Inflammatory Disease I: Expanding the Spectrum of Clinical Features in Rheumatological Disorders (903–908)

4:30PM-6:00PM: 3S105: Osteoarthritis & Joint Biology – Basic Science (886–891)

4:30PM-6:00PM: 3S106: Osteoarthritis – Clinical I: Innovations (909–914)

4:30PM-6:00PM: 3S107: Pediatric Rheumatology – Clinical I: Systemic JIA (915–920)

4:30PM-6:00PM: 3S108: RA – Diagnosis, Manifestations, & Outcomes II: Cardiovascular Comorbidities (921–926)

4:30PM-6:00PM: 3S109: RA – Treatments II: Novel Treatments for RA (927–932)

4:30PM-6:00PM: 3S110: SLE – Clinical III: Clinical Trials II (939–944)

4:30PM-6:00PM: 3S111: Spondyloarthritis Including Psoriatic Arthritis – Clinical II: Axial Spondyloarthritis Treatment (933–938)

4:30PM-6:00PM: 3S112: Vasculitis – Non-ANCA-Associated & Related Disorders I: Miscellaneous Disorders (945–950)

Monday, November 11, 2019

9:00AM-11:00AM: B Cell Biology & Targets In Autoimmune & Inflammatory Disease Poster

9:00AM-11:00AM: Epidemiology & Public Health Poster II: Spondyloarthritis & Connective Tissue Disease

9:00AM-11:00AM: Health Services Research Poster II – ACR/ARP

9:00AM-11:00AM: Healthcare Disparities In Rheumatology Poster

9:00AM-11:00AM: Imaging Of Rheumatic Diseases Poster II

9:00AM-11:00AM: Measures Of Healthcare Quality Poster II: Improving Care

9:00AM-11:00AM: Metabolic & Crystal Arthropathies Poster II: Clinical Trials & Basic Science

9:00AM-11:00AM: Miscellaneous Rheumatic & Inflammatory Disease Poster II: Autoinflammation Related Diseases & Therapies

9:00AM-11:00AM: Muscle Biology, Myositis & Myopathies Poster II

9:00AM-11:00AM: Osteoarthritis – Clinical Poster I

9:00AM-11:00AM: Pediatric Rheumatology – ePoster II: SLE, Juvenile Dermatomyositis, & Scleroderma

9:00AM-11:00AM: Pediatric Rheumatology – ePoster II: SLE, Juvenile Dermatomyositis, & Scleroderma – ARP

9:00AM-11:00AM: RA – Animal Models Poster

9:00AM-11:00AM: RA – Diagnosis, Manifestations, & Outcomes Poster II: Treatments, Outcomes, & Measures

9:00AM-11:00AM: RA – Diagnosis, Manifestations, & Outcomes Poster II: Treatments, Outcomes, & Measures – ARP

9:00AM-11:00AM: RA – Treatments Poster II: Established Treatments

9:00AM-11:00AM: Sjögrenʼs Syndrome – Basic & Clinical Science Poster II

9:00AM-11:00AM: SLE – Clinical Poster II: Comorbidities

9:00AM-11:00AM: SLE – Etiology & Pathogenesis Poster I

9:00AM-11:00AM: Spondyloarthritis Including Psoriatic Arthritis – Basic Science Poster

9:00AM-11:00AM: Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Treatment of Axial Spondyloarthritis & Psoriatic Arthritis

9:00AM-11:00AM: Systemic Sclerosis & Related Disorders – Basic Science Poster

9:00AM-11:00AM: Systemic Sclerosis & Related Disorders – Clinical Poster II

9:00AM-11:00AM: Vasculitis – ANCA-Associated Poster II

9:00AM-11:00AM: Vasculitis – Non-ANCA-Associated & Related Disorders Poster III: Behçet’s Disease & Other Vasculitides

11:00AM-12:30PM: 4M046: Plenary II (1758–1763)

2:30PM-4:00PM: 3S082: SLE – Clinical II: Flares & Morbidity of SLE (1824–1829)

2:30PM-4:00PM: 4M087: Antiphospholipid Syndrome (1788–1793)

2:30PM-4:00PM: 4M088: Cytokines & Cell Trafficking (1764–1769)

2:30PM-4:00PM: 4M089: Education (1794–1799)

2:30PM-4:00PM: 4M090: Infection-Related Rheumatic Disease (1800–1805)

2:30PM-4:00PM: 4M091: Miscellaneous Rheumatic & Inflammatory Disease II: Checkpoint Inhibitors-Induced & Other Rheumatic Conditions (1806–1811)

2:30PM-4:00PM: 4M092: Pediatric Rheumatology – Clinical II: JIA (1812–1817)

2:30PM-4:00PM: 4M093: RA – Animal Models (1770–1775)

2:30PM-4:00PM: 4M094: SLE – Animal Models (1782–1787)

2:30PM-4:00PM: 4M095: Spondyloarthritis Including Psoriatic Arthritis – Basic Science (1776–1781)

2:30PM-4:00PM: 4M096: Spondyloarthritis Including Psoriatic Arthritis – Clinical III: Miscellaneous (1818–1823)

2:30PM-4:00PM: 4M097: Systemic Sclerosis & Related Disorder – Clinical II: Cardiopulmonary Involvement (1830–1835)

2:30PM-4:00PM: 4M098: Vasculitis – Non-ANCA-Associated & Related Disorders II: Large Vessel Vasculitis Treatment (1836–1841)

2:30PM-4:00PM: 4M127: Pain, Anxiety, & Depression (1842–1847)

4:30PM-6:00PM: 4M110: Healthcare Disparities in Rheumatology (1848–1853)

4:30PM-6:00PM: 4M111: Imaging of Rheumatic Diseases I (1854–1859)

4:30PM-6:00PM: 4M112: Measures of Healthcare Quality I: Digital Health Technologies – Tool for Improvement (1860–1865)

4:30PM-6:00PM: 4M113: Muscle Biology, Myositis & Myopathies I (1866–1871)

4:30PM-6:00PM: 4M114: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science (1872–1877)

4:30PM-6:00PM: 4M115: Pain Mechanisms – Basic & Clinical Science (1878–1883)

4:30PM-6:00PM: 4M116: RA – Diagnosis, Manifestations, & Outcomes III: Diagnosis & Prognosis (1884–1889)

4:30PM-6:00PM: 4M117: RA – Treatments III: Cardiovascular Disease & Readmissions (1890–1895)

4:30PM-6:00PM: 4M118: Reproductive Issues in Rheumatic Disorders (1896–1901)

4:30PM-6:00PM: 4M119: Sjögrenʼs Syndrome – Basic & Clinical Science (1902–1907)

4:30PM-6:00PM: 4M120: SLE – Clinical IV: Lupus Nephritis (1914–1919)

4:30PM-6:00PM: 4M121: Spondyloarthritis Including Psoriatic Arthritis – Clinical IV: Axial Spondyloarthritis Translational Research (1908–1913)

4:30PM-6:00PM: 4M125: Pediatric Rheumatology: Outcomes & Quality of Life (1920–1925)

Tuesday, November 12, 2019

9:00AM-11:00AM: Epidemiology & Public Health Poster III: OA, Gout, & Other Diseases

9:00AM-11:00AM: Epidemiology & Public Health Poster III: OA, Gout, & Other Diseases – ARP

9:00AM-11:00AM: Genetics, Genomics & Proteomics Poster

9:00AM-11:00AM: Infection-Related Rheumatic Disease Poster

9:00AM-11:00AM: Late-Breaking Abstracts ePoster

9:00AM-11:00AM: Miscellanous Rheumatic & Inflammatory Disease Poster III: Autoimmune Conditions and Therapies

9:00AM-11:00AM: Orthopedics, Low Back Pain, & Rehabilitation Poster – ACR/ARP

9:00AM-11:00AM: Osteoarthritis – Clinical Poster II

9:00AM-11:00AM: Osteoarthritis & Joint Biology – Basic Science Poster

9:00AM-11:00AM: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster

9:00AM-11:00AM: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster – ARP

9:00AM-11:00AM: Patient Outcomes, Preferences, & Attitudes Poster II: Patient Preferences, Beliefs, & Experiences

9:00AM-11:00AM: Patient Outcomes, Preferences, & Attitudes Poster II: Patient Preferences, Beliefs, & Experiences – ARP

9:00AM-11:00AM: Pediatric Rheumatology – ePoster III: Systemic JIA, Fever, & Vasculitis

9:00AM-11:00AM: Pediatric Rheumatology – ePoster III: Systemic JIA, Fever, & Vasculitis – ARP

9:00AM-11:00AM: Psychology/Social Science Poster – ARP

9:00AM-11:00AM: RA – Diagnosis, Manifestations, & Outcomes Poster III: Comorbidities

9:00AM-11:00AM: RA – Etiology & Pathogenesis Poster II

9:00AM-11:00AM: RA – Treatments Poster III: Safety and Outcomes

9:00AM-11:00AM: RA – Treatments Poster III: Safety and Outcomes – ARP

9:00AM-11:00AM: Reproductive Issues In Rheumatic Disorders Poster

9:00AM-11:00AM: Research Methodology Poster – ARP

9:00AM-11:00AM: Sjögrenʼs Syndrome – Basic & Clinical Science Poster I

9:00AM-11:00AM: SLE – Clinical Poster III: Treatment

9:00AM-11:00AM: SLE – Etiology & Pathogenesis Poster II

9:00AM-11:00AM: Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Psoriatic Arthritis, Clinical Features

9:00AM-11:00AM: Systemic Sclerosis & Related Disorders – Clinical Poster III

9:00AM-11:00AM: Vasculitis – ANCA-Associated Poster I

9:00AM-11:00AM: Vasculitis – Non-ANCA-Associated & Related Disorders Poster III: Giant Cell Arteritis

11:00AM-12:30PM: 5T047: Plenary III (2727–2732)

2:30PM-4:00PM: 5T087: Edmond L. Dubois, MD Memorial Lecture: SLE – Basic Science (2733–2737)

2:30PM-4:00PM: 5T088: Genetics, Genomics & Proteomics (2738–2743)

2:30PM-4:00PM: 5T089: Imaging of Rheumatic Diseases II (2750–2755)

2:30PM-4:00PM: 5T090: Osteoarthritis – Clinical II: Novel Therapies (2756–2761)

2:30PM-4:00PM: 5T091: Patient Outcomes, Preferences, & Attitudes II: Patient Preferences, Beliefs, & Experiences (2762–2767)

2:30PM-4:00PM: 5T092: RA – Treatments IV: Novel Therapy & Predicting Response (2768–2773)

2:30PM-4:00PM: 5T093: SLE – Clinical V: Emerging Knowledge of Current Treatments (2780–2785)

2:30PM-4:00PM: 5T094: Spondyloarthritis Including Psoriatic Arthritis – Clinical V: Axial Spondyloarthritis Clinical Studies (2774–2779)

2:30PM-4:00PM: 5T095: Systemic Sclerosis & Related Disorder – Basic Science (2744–2749)

2:30PM-4:00PM: 5T096: Vasculitis – ANCA-Associated II (2786–2791)

2:30PM-4:00PM: 5T098: Orthopedics, Low Back Pain & Rehabilitation (2798–2803)

2:30PM-4:00PM: 5T101: Clinical Aspects & Outcomes Research (2792–2797)

4:00PM-6:00PM: 5T132: Late-Breaking Abstracts

4:30PM-6:00PM: 5T109: Epidemiology & Public Health III: RA (2822–2827)

4:30PM-6:00PM: 5T110: Innate Immunity (2804–2809)

4:30PM-6:00PM: 5T111: Measures of Healthcare Quality II: Quality Improvement in Rheumatology – Still Getting Better (2828–2833)

4:30PM-6:00PM: 5T112: Metabolic & Crystal Arthropathies II: Genetics & Physiology (2834–2839)

4:30PM-6:00PM: 5T113: Muscle Biology, Myositis & Myopathies II (2840–2845)

4:30PM-6:00PM: 5T114: RA – Diagnosis, Manifestations, & Outcomes IV: Outcomes (2846–2851)

4:30PM-6:00PM: 5T115: SLE – Etiology & Pathogenesis I: Signaling Pathways (2810–2815)

4:30PM-6:00PM: 5T116: Spondyloarthritis Including Psoriatic Arthritis – Clinical VI: Psoriatic Arthritis Clinical Studies (2852–2857)

4:30PM-6:00PM: 5T117: T Cell Biology & Targets in Autoimmune & Inflammatory Disease (2816–2821)

Wednesday, November 13, 2019

9:00AM-10:30AM: 6W010: Pediatric Rheumatology – Clinical III: Juvenile SLE & Dermatomyositis (2864–2869)

9:00AM-10:30AM: 6W011: RA – Diagnosis, Manifestations, & Outcomes V: Treatment (2870–2875)

9:00AM-10:30AM: 6W012: RA – Etiology & Pathogenesis II (2858–2863)

9:00AM-10:30AM: 6W013: SLE – Clinical VI: Epidemiology, Diagnosis, & Outcomes (2882–2887)

9:00AM-10:30AM: 6W014: Spondyloarthritis Including Psoriatic Arthritis – Clinical VII: Psoriatic Arthritis Treatment (2876–2881)

9:00AM-10:30AM: 6W017: Health Services Research II: Health Economics (2888–2893)

11:00AM-12:30PM: 6W020: Miscellaneous Rheumatic & Inflammatory Disease III: Novel Therapies (2900–2905)

11:00AM-12:30PM: 6W021: RA – Treatments V: Switching & Tapering RA Medications (2906–2911)

11:00AM-12:30PM: 6W022: SLE – Etiology & Pathogenesis II (2894–2899)

11:00AM-12:30PM: 6W023: Systemic Sclerosis & Related Disorder – Clinical III: Predictors of Outcome (2912–2917)

11:00AM-12:30PM: 6W024: Vasculitis – Non-ANCA-Associated & Related Disorders III: Large Vessel Vasculitis Pathogenesis & Imaging (2918–2923)

11:00AM-12:30PM: 6W026: Epidemiology & Public Health (2924–2929)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].